Novartis AG (ADR) (NYSE:NVS) announced today the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for marketing approval for the use of Bexsero® (Multicomponent Meningococcal Group B Vaccine [recombinant, adsorbed]) to help protect against invasive meningococcal disease caused by serogroup B (meningitis B) in adolescents and young adults from 10 years through 25 years of age. Novartis AG (ADR) (NYSE:NVS) stock performance was 1.18% in last session and finished the day at $90.39. Traded volume was 972.40K shares in the last session and the average volume of the stock remained 1.77million shares. The beta of the stock remained 0.61.
IMAX Corporation (USA) (NYSE:IMAX) shares rose Monday after the large-screen movie company announced a $150 million stock buyback program. The company said the program – slated to run up to three years – reflects its strong financial position and positive expectations for its future cash position as well as its focus on returning value to shareholders. IMAX Corporation (USA) (NYSE:IMAX) rose 3.22 percent to $27.85 Monday on volume of 778.50K shares. The intra-day range of the stock was $27.40 to $28.00. IMAX Corporation (USA) (NYSE:IMAX) has a market capitalization of $1.90billion.
Immunogen, Inc. (NASDAQ:IMGN) disclosed for the first time preclinical data for IMGN779. The data were presented at the 19th Congress of the European Hematology Association (EHA) meeting in Milan, Italy (abstract# P802). IMGN779 is a novel, CD33-targeting, DNA-alkylating ADC that is a potential treatment for acute myeloid leukemia (AML). ImmunoGen, Inc. (NASDAQ:IMGN)’s stock on June 16, 2014 reported a increase of 0.23% to the closing price of $13.29. Its fifty two weeks range is $10.69 -$20.25. The total market capitalization recorded $1.14billion. The overall volume in the last trading session was 512.40K shares. In its share capital, IMGN has 85.81million outstanding shares.
bluebird bio, Inc. (NASDAQ:BLUE) released initial positive clinical data from its HGB-205 clinical study of its LentiGlobin BB305 product candidate in beta-thalassemia major subjects at the 19th Annual Congress of the European Hematology Association (EHA) in Milan, Italy. On Monday, shares of bluebird bio Inc (NASDAQ:BLUE) advanced 32.08% to close the day at $34.46. Company return on investment (ROI) is -16.40% and its monthly performance is recorded as 40.54%. bluebird bio Inc (NASDAQ:BLUE) quarterly revenue growth is 26.69%.
Randgold Resources Ltd. (NASDAQ:GOLD)’s stock had its “overweight” rating reiterated by analysts at Barclays in a research report issued to clients and investors on Monday. Randgold Resources Ltd. (ADR) (NASDAQ:GOLD) stock performance was 1.05% in last session and finished the day at $78.32. Traded volume was 6,800.00million shares in the last session and the average volume of the stock remained 534.95K shares. The beta of the stock remained 0.45.